Status: Not yet recruiting
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency
Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma with Mismatch Repair Deficiency.
Participants needed: 8
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Jennifer LeddonUpdated: Feb 4, 2026Locations: 1
Eligibility criteria
Patient previously diagnosed with WHO grade 4 IDH-wildtype GBM, determined throu... [+8]
Multifocal or leptomeningeal disease observed at the time of GBM recurrence. [+9]